文献速递肾癌与肾肿瘤

中高危非转移性肾细胞癌术后局部复发的解剖分类与ASSURE试验分析

Local Recurrence Following Resection of Intermediate-High Risk Nonmetastatic Renal Cell Carcinoma: An Anatomical Classification and Analysis of the ASSURE (ECOG-ACRIN E2805) Adjuvant Trial.
PubMed 文献 · J Urol · 2019-10-09

基于ASSURE(ECOG-ACRIN E2805)前瞻性随机对照数据,对1943例完全切除的中高危非转移性肾细胞癌患者中300例(15.4%)局部复发进行解剖分类(I-IV型)。结果显示手术方式与术式不预测局部复发,IV型复发者5年肿瘤特异性生存和总生存更差(均p<0.001),I-III型间生存无差异。

要点

  • 局部复发更多反映肿瘤生物学行为,而非手术微创与否或部分/根治术式。
  • 孤立性腹腔内局部复发(I-III型)无论位置预后相似。
  • 多部位/多亚型复发(IV型)与更差生存相关。

核心结论

  • 中高危非转移性肾细胞癌局部复发似乎是生物学行为而非手术方式或术式的函数。
  • 孤立性腹腔内局部复发(I-III型)预后相似,而涉及多部位和/或多亚型的复发(IV型)与更差生存相关。

研究设计与样本

  • 基于ASSURE(ECOG-ACRIN E2805)前瞻性随机对照试验数据的回顾性分析。
  • 纳入1943例完全切除的中高危非转移性肾细胞癌患者,其中300例(15.4%)发生局部复发。

主要发现

  • 300例局部复发中,I型66例(22.0%)、II型97例(32.3%)、III型87例(29.0%)、IV型50例(16.7%)。
  • 手术方式(微创 vs 开放)和手术类型(部分 vs 根治)均不预测任何局部复发。
  • IV型复发患者5年肿瘤特异性生存和总生存更差(均p<0.001)。
  • I-III型复发患者间生存无差异。

关键数值与推荐

  • I型:残余肾或同侧肾窝单发复发;II型:同侧血管、同侧肾上腺或淋巴结单发复发;III型:其他腹腔内软组织或器官单发复发;IV型:I-III型任意组合或单一类型多发复发。

临床怎么用

  • 局部复发解剖分类可用于预后分层,IV型复发患者需更密切随访和积极干预。
  • 手术方式选择(微创或开放、部分或根治)不应基于局部复发风险而改变。

局限性

  • 原文未报告

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We describe what is to our knowledge a novel classification system for local recurrence after surgery of renal cell carcinoma. We assessed its prognostic implications using prospective, randomized controlled data. MATERIALS AND METHODS: We queried the ASSURE (Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery) (ECOG-ACRIN [Eastern Cooperative Oncology Group-American College of Radiology Imaging Network] E2805) trial data for patients with fully resected, intermediate-high risk, nonmetastatic renal cell carcinoma with local recurrence. We used certain definitions, including type I-single recurrence in a remnant kidney or ipsilateral renal fossa, type II-single recurrence in the ipsilateral vasculature, the ipsilateral adrenal gland or a lymph node, type III-single recurrence in other intra-abdominal soft tissues or organs and type IV-any combination of types I-III or multiple recurrences of a single type. Multivariable logistic regression and the log rank test were performed to identify clinicopathological predictors and compare survival, respectively. RESULTS: Of the 1,943 patients 300 (15.4%) had local recurrence, which was type I, II, III and IV in 66 (22.0%), 97 (32.3%), 87 (29.0%) and 50 (16.7%), respectively. Surgical modality (minimally invasive vs open) and type of surgery (partial vs radical) did not predict any local recurrence. Five-year cancer specific survival and overall survival were worse in patients with type IV recurrence (each p <0.001). There was no difference in survival among patients with types I to III recurrence. CONCLUSIONS: In patients with intermediate-high risk nonmetastatic renal cell carcinoma local recurrence appears to be a function of biology more than of surgical modality or surgery type. The prognosis for solitary intra-abdominal local recurrences appear similar regardless of location (types I-III). Local recurrences involving multiple sites and/or subdivisions are associated with worse survival (type IV).

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Lee Z, Jegede OA, Haas NB, et al. Local Recurrence Following Resection of Intermediate-High Risk Nonmetastatic Renal Cell Carcinoma: An Anatomical Classification and Analysis of the ASSURE (ECOG-ACRIN E2805) Adjuvant Trial. J Urol. 2019. PMID: 31596672. doi:10.1097/JU.0000000000000588

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。